31st International Meeting on Advanced Spine Techniques (IMAST)
San Diego, California, USA
April 10-13, 2024
Abstracts NOW open!
Submit an IMAST Abstract Submit Your Disclosure
|July 1, 2023
||Abstract Submission Open
|October 2, 2023
||Abstract Submission Closes
|Early December 2023
||Abstract Acceptance Notifications
||Acceptance and Registration Deadline
All abstracts must be submitted online by Monday, October 2, 2023. No exceptions will be made.
Abstract submission to IMAST must fit into one of the following categories to be considered for presentation. Authors can choose optional sub-categories to further classify their topic. More than one sub-category can be selected:
- Adolescent Idiopathic Scoliosis
- Adult Spinal Deformity
- Basic Science, Biomechanics/Genetics
- Cervical Spine: Deformity, Degenerative
- Complex: Spondylolisthesis, Tumor, Trauma
- Degenerative Spinal Deformity
- Early Onset Scoliosis
- Kyphotic Deformities
- Neuromuscular Scoliosis
- Minimally Invasive
- Motion Preservation
- Novel Technique
- Maximum of 2,250 characters
- Characters in the abstract title, body and table/image caption will be counted (including spaces)
- Characters in the author and institution listing will not be counted.
- Limited to one graph, figure, or table for each submitted abstract. No exceptions will be made.
Disclosure and Licensing Requirement
ALL authors listed on an abstract will be required to submit a:
- Financial disclosure form, including disclosure of ALL financial relationships, not only those pertaining to the topic of the abstract, from the past 24 months.
- FDA Disclosure Form
- Attestation and Non-exclusive License Form
If authors on an abstract have not completed these required forms prior to the submission deadline, the abstract will NOT be reviewed or considered for the meeting program.
*Abstracts with authors missing a completed Financial Relationship Disclosure will NOT be reviewed.
Visit this link to disclose: https://owpm1.com/abstracts/IMAST/disclosure
The username is the email associated with your abstract and the password your first name.
Previous Publication or Presentation
Abstracts which have been published in journals, meeting proceedings, or other publications, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit, are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.
SRS strongly prefers that pharmaceuticals and proprietary software/databases as well as surgical approaches or specific instrumentation such as “Surgimap, MIMICS, EOS Imaging, ROTEM, Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR etc.,” are not used in presentations. These terms should be replaced by a generic term or description of the drug, software/database and/or instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque).
It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, expanded verbal disclosure will be necessary at the time of presentation.
Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.
All abstracts submitted will be reviewed and graded in blinded fashion by the IMAST Committee. Two-year follow-up is required for papers submitted to the Annual Meeting. Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or three-minute E-Point presentation. Acceptance notification will be sent in December 2023.
By submitting an abstract to the Annual Meeting, abstract authors agree that at least one (1) author will attend the meeting and will be available to present on the date and time assigned.
In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth will automatically be withdrawn from the program.
All travel arrangements are the responsibility of the authors.
All selected authors will be required to respond to a formal invitation by the deadline set forth in their acceptance notification.
Authors without an account AND an updated disclosure cannot be added after this date. No exceptions will be made.
Podium Presentation Cancellation & No-Show Policy
Authors unable to present their paper in person should inform SRS as soon as possible with a co-author that can attend to present the paper. If no one can attend in person, please inform SRS by January, so an alternate paper can be substituted.
Please note: In the case of a "no-show" podium presentation, the presenting author associated with the "no-show" paper will be prohibited from presenting any papers at the next two Annual Meetings.
E-Point Presentation Cancellation Policy
At least one author or co-author on all E-Point presentations is expected to register to attend the meeting by the deadline set forth in their acceptance notification.
If this author cancels their registration prior to the meeting, the E-Point presentation may be withdrawn from the program.
All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found.
Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one-year ban for abstract presentations and a three-year ban for invited presentations.
Back to Top